Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb;51(2):466-474.
doi: 10.1007/s11239-020-02195-4.

Validation of the adjusted global antiphospholipid syndrome score in a single centre cohort of APS patients from Turkey

Ömer Uludağ  1 , Murat Bektaş  2 , Erhan Çene  3 , Murat Sezer  4 , Yasemin Şahinkaya  2 , Ahmet Gül  2 , Murat Inanç  2 , Lale Öcal  2 , Bahar Artim-Esen  2
Affiliations

Validation of the adjusted global antiphospholipid syndrome score in a single centre cohort of APS patients from Turkey

Ömer Uludağ et al. J Thromb Thrombolysis. 2021 Feb.

Abstract

The adjusted global antiphospholipid syndrome score (aGAPSS) is a recently developed thrombotic risk assessment score that considers the antiphospholipid antibody (aPL) profile and conventional cardiovascular risk factors. In this retrospective study, we aimed to evaluate the validity of the aGAPSS in predicting clinical manifestations (criteria and extra-criteria) of antiphospholipid syndrome (APS) in a single centre cohort of patients. Ninety-eight patients with APS ± systemic lupus erythematosus (SLE) were classified according to clinical manifestations as vascular thrombosis (VT), pregnancy morbidity (PM) or both (VT + PM). The aGAPSS was calculated for each patient as previously defined. Mean aGAPSS of the cohort was calculated as 10.2 ± 3.8. Significantly higher aGAPSS values were seen in VT (n = 58) and VT + PM (n = 29) groups when compared to PM (n = 11) group (10.6 ± 3.7 vs 7.4 ± 2.9, P = 0.005; 10.7 ± 4 vs 7.4 ± 2.9, P = 0.008, respectively), mainly due to lower frequencies of cardiovascular risk factors in PM. Higher aGAPPS values were also associated with recurrent thrombosis (11.6 ± 3.7 vs 9.9 ± 3.6, P = 0.04). Regarding extra-criteria manifestations, patients with livedo reticularis (n = 11) and APS nephropathy (n = 9) had significantly higher aGAPSS values (12.9 ± 3.4 vs 9.9 ± 3.7, P = 0.02; 12.4 ± 2.9 vs 10 ± 3.8, P = 0.04, respectively). The computed AUC demonstrated that aGAPSS values ≥10 had the best diagnostic accuracy for thrombosis. Our results suggest that patients with higher aGAPSS values are at higher risk for developing vascular thrombosis (either first event or recurrence) and extra-criteria manifestations, especially livedo reticularis and APS nephropathy.

Keywords: Adjusted global antiphospholipid syndrome score; Antiphospholipid syndrome; Vascular thrombosis risk.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Miyakis S, Lockshin MD, Atsumi T et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306. https://doi.org/10.1111/j.1538-7836.2006.01753.x - DOI - PubMed
    1. Petri M, Orbai AM, Alarcon GS et al (2012) Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677–2686. https://doi.org/10.1002/art.34473 - DOI - PubMed - PMC
    1. Willis R, Pierangeli SS (2011) Pathophysiology of the antiphospholipid antibody syndrome. Auto Immun Highlights 2(2):35–52. https://doi.org/10.1007/s13317-011-0017-9 - DOI - PubMed - PMC
    1. Galli M, Luciani D, Bertolini G, Barbui T (2003) Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101:1827–1832. https://doi.org/10.1182/blood-2002-02-0441 - DOI - PubMed
    1. Ruffatti A, Del Ross T, Ciprian M et al (2011) Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis 70(6):1083–1086. https://doi.org/10.1136/ard.2010.142042 - DOI - PubMed

Substances

LinkOut - more resources